TrialEuropean journal of cancer (Oxford, England : 1990)2019

Phase II trial of the glycoprotein non-metastatic B-targeted antibody-drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: A report from the Children's Oncology Group.

Lisa M Kopp et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.